Suvratoxumab - MedImmune

Drug Profile

Suvratoxumab - MedImmune

Alternative Names: Human immunoglobulin G1 kappa monoclonal antibody; MEDI-4893

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer MedImmune
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nosocomial pneumonia

Most Recent Events

  • 07 May 2018 Phase-II clinical trials in Nosocomial pneumonia (Prevention) in USA (IV) before May 2018 (NCT02296320)
  • 21 Apr 2018 Pharmacodynamics data from preclinical trials in Nosocomial pneumonia (Prevention) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 21 Apr 2018 Interim pharmacokinetics data from a phase II trial in nosocomial pneumonia presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID - 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top